| Description |
AZD2906 is a selective glucocorticoid receptor (GR) agonist, with IC50s of 2.2, 0.3, 41.6 and 7.5 nM at GR in human, rat PBMC and human, rat whole blood, respectively. AZD2906 increases micronucleated immature erythrocytes (MIE) in the bone marrow of rats[1].
|
| Related Catalog |
|
| Target |
IC50: 2.2 nM (Glucocorticoid receptor, Human PBMC), 0.3 nM (Glucocorticoid receptor, Rat PBMC), 41.6 nM (Glucocorticoid receptor, Human whole blood), 7.5 nM (Glucocorticoid receptor, Rat whole blood)[1]
|
| In Vitro |
AZD2906 is a selective glucocorticoid receptor (GR), with IC50s of 2.2, 0.3, 41.6 and 7.5 nM at GR in human, rat PBMC and human, rat whole blood, respectively[1].
|
| In Vivo |
AZD2906 (5, 25, 50 mg/kg, p.o.) increases micronucleated immature erythrocytes (MIE) in the bone marrow of rats after treatment for 2 days[1]. AZD2906 (5, 25 mg/kg, p.o.) induces an accumulation of glycogen in the liver of rats, and exhibits cortical lymphocytic atrophy of a moderate to marked degree in the thymus of rats[1]. Animal Model: Male Wistar Han rats (10 weeks old)[1] Dosage: 5, 25, 50 mg/kg Administration: P.O. for 2 days Result: Caused significant increases in micronucleated immature erythrocytes (MIE) at all doses after analysis of the standard 2000 IE.
|
| References |
[1]. Hayes JE, et al. Micronucleus induction in the bone marrow of rats by pharmacological mechanisms. I: glucocorticoid receptor agonism. Mutagenesis. 2013 Mar;28(2):227-32.
|
